Advertisement

Increased MDR1 Transporter Expression in Human Brain Endothelial Cells Through Enhanced Histone Acetylation and Activation of Aryl Hydrocarbon Receptor Signaling

  • Dahea You
  • Xia Wen
  • Ludwik Gorczyca
  • Ayeshia Morris
  • Jason R. Richardson
  • Lauren M. AleksunesEmail author
Article
  • 78 Downloads

Abstract

Multidrug resistance protein 1 (MDR1, ABCB1, P-glycoprotein) is a critical efflux transporter that extrudes chemicals from the blood–brain barrier (BBB) and limits neuronal exposure to xenobiotics. Prior studies in malignant cells demonstrated that MDR1 expression can be altered by inhibition of histone deacetylases (HDAC), enzymes that modify histone structure and influence transcription factor binding to DNA. Here, we sought to identify the mechanisms responsible for the up-regulation of MDR1 by HDAC inhibitors in human BBB cells. Immortalized human brain capillary endothelial (hCMEC/D3) cells were treated with HDAC inhibitors and assessed for MDR1 expression and function. Of the HDAC inhibitors profiled, valproic acid (VPA), apicidin, and suberoylanilide hydroxamic acid (SAHA) increased MDR1 mRNA and protein levels by 30–200%, which corresponded with reduced intracellular accumulation of the MDR1 substrate rhodamine 123. Interestingly, induction of MDR1 mRNA by HDAC inhibitors mirrored increases in the expression of the aryl hydrocarbon receptor (AHR) and its target gene cytochrome P450 1A1. To explore the role of AHR in HDAC inhibitor-mediated regulation of MDR1, a pharmacological activator (β-naphthoflavone, βNF) and inhibitor (CH-223191, CH) of AHR were tested. The induction of MDR1 in cells treated with SAHA was amplified by βNF and attenuated by CH. Furthermore, SAHA increased the binding of acetylated histone H3K9/K14 and AHR proteins to regions of the MDR1 promoter that contain AHR response elements. In conclusion, HDAC inhibitors up-regulate the expression and activity of the MDR1 transporter in human brain endothelial cells by increasing histone acetylation and facilitating AHR binding at the MDR1 promoter.

Keywords

MDR1 HDAC Transport Blood–brain barrier Aryl hydrocarbon receptor 

Notes

Authors’ Contributions

Participated in research design: D.Y., X.W., J.R.R., L.M.A.

Conducted experiments: D.Y., L.G., A.M.

Performed data analysis: D.Y., A.M.

Wrote or contributed to the writing of the manuscript: D.Y., J.R.R., L.M.A.

Funding Information

This work was supported by the National Institutes of Health–National Institute of Environmental Health Sciences (grant numbers R01ES021800, R01ES026057, T32ES007148, F31ES029794, and P30ES005022) and a Graduate Fellowship from Bristol-Myers Squibb to D.Y. Neither NIEHS nor Bristol-Myers Squibb had any role in the conduct of the study, interpretation of data, or decision to publish. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or Bristol-Myers Squibb.

Compliance with Ethical Standards

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Supplementary material

12035_2019_1565_MOESM1_ESM.xlsx (23 kb)
ESM 1 (XLSX 23 kb)
12035_2019_1565_MOESM2_ESM.docx (13.1 mb)
ESM 2 (DOCX 13396 kb)

References

  1. 1.
    Abbott NJ (2014) Anatomy and physiology of the blood–brain barriers. In: Hammarlund-Udenaes M, de Lange E, Thorne RG (eds) Drug delivery to the brain: physiological concepts, methodologies and approaches, vol 10. 1 edn. Springer-Verlag, New York, pp 731Google Scholar
  2. 2.
    Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ (2010) Structure and function of the blood–brain barrier. Neurobiol Dis 37(1):13–25.  https://doi.org/10.1016/j.nbd.2009.07.030 CrossRefPubMedGoogle Scholar
  3. 3.
    Loscher W, Potschka H (2005) Blood–brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2(1):86–98.  https://doi.org/10.1602/neurorx.2.1.86 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Nakanishi T, Ross DD (2012) Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression. Chin J Cancer 31(2):73–99.  https://doi.org/10.5732/cjc.011.10320 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Sadhasivam S, Chidambaran V, Zhang X, Meller J, Esslinger H, Zhang K, Martin LJ, McAuliffe J (2015) Opioid-induced respiratory depression: ABCB1 transporter pharmacogenetics. Pharmacogenomics J 15(2):119–126.  https://doi.org/10.1038/tpj.2014.56 CrossRefPubMedGoogle Scholar
  6. 6.
    Xie R, Hammarlund-Udenaes M, de Boer AG, de Lange EC (1999) The role of P-glycoprotein in blood–brain barrier transport of morphine: transcortical microdialysis studies in mdr1a (−/−) and mdr1a (+/+) mice. Br J Pharmacol 128(3):563–568.  https://doi.org/10.1038/sj.bjp.0702804 CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Chan YY, Kalpana S, Chang WC, Chang WC, Chen BK (2013) Expression of aryl hydrocarbon receptor nuclear translocator enhances cisplatin resistance by upregulating MDR1 expression in cancer cells. Mol Pharmacol 84(4):591–602.  https://doi.org/10.1124/mol.113.087197 CrossRefPubMedGoogle Scholar
  8. 8.
    Cornwell MM (1990) The human multidrug resistance gene: sequences upstream and downstream of the initiation site influence transcription. Cell Growth Differ 1(12):607–615PubMedGoogle Scholar
  9. 9.
    Deng L, Lin-Lee YC, Claret FX, Kuo MT (2001) 2-Acetylaminofluorene up-regulates rat mdr1b expression through generating reactive oxygen species that activate NF-kappa B pathway. J Biol Chem 276(1):413–420.  https://doi.org/10.1074/jbc.M004551200 CrossRefPubMedGoogle Scholar
  10. 10.
    Geick A, Eichelbaum M, Burk O (2001) Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 276(18):14581–14587.  https://doi.org/10.1074/jbc.M010173200 CrossRefPubMedGoogle Scholar
  11. 11.
    Goldsmith ME, Madden MJ, Morrow CS, Cowan KH (1993) A Y-box consensus sequence is required for basal expression of the human multidrug resistance (mdr1) gene. J Biol Chem 268(8):5856–5860PubMedGoogle Scholar
  12. 12.
    Gromnicova R, Romero I, Male D (2012) Transcriptional control of the multi-drug transporter ABCB1 by transcription factor Sp3 in different human tissues. PLoS One 7(10):e48189.  https://doi.org/10.1371/journal.pone.0048189 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Jin S, Scotto KW (1998) Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y. Mol Cell Biol 18(7):4377–4384CrossRefGoogle Scholar
  14. 14.
    Madden MJ, Morrow CS, Nakagawa M, Goldsmith ME, Fairchild CR, Cowan KH (1993) Identification of 5′ and 3′ sequences involved in the regulation of transcription of the human mdr1 gene in vivo. J Biol Chem 268(11):8290–8297PubMedGoogle Scholar
  15. 15.
    Ogura M, Takatori T, Sugimoto Y, Tsuruo T (1991) Identification and characterization of three DNA-binding proteins on the promoter of the human MDR1 gene in drug-sensitive and -resistant cells. Jpn J Cancer Res 82(10):1151–1159CrossRefGoogle Scholar
  16. 16.
    Scotto KW (2003) Transcriptional regulation of ABC drug transporters. Oncogene 22(47):7496–7511.  https://doi.org/10.1038/sj.onc.1206950 CrossRefPubMedGoogle Scholar
  17. 17.
    Ueda K, Clark DP, Chen CJ, Roninson IB, Gottesman MM, Pastan I (1987) The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation. J Biol Chem 262(2):505–508PubMedGoogle Scholar
  18. 18.
    Ueda K, Pastan I, Gottesman MM (1987) Isolation and sequence of the promoter region of the human multidrug-resistance (P-glycoprotein) gene. J Biol Chem 262(36):17432–17436PubMedGoogle Scholar
  19. 19.
    Cary PD, Crane-Robinson C, Bradbury EM, Dixon GH (1982) Effect of acetylation on the binding of N-terminal peptides of histone H4 to DNA. Eur J Biochem 127(1):137–143CrossRefGoogle Scholar
  20. 20.
    Hong L, Schroth GP, Matthews HR, Yau P, Bradbury EM (1993) Studies of the DNA binding properties of histone H4 amino terminus. Thermal denaturation studies reveal that acetylation markedly reduces the binding constant of the H4 "tail" to DNA. J Biol Chem 268(1):305–314PubMedGoogle Scholar
  21. 21.
    Sung MT, Dixon GH (1970) Modification of histones during spermiogenesis in trout: a molecular mechanism for altering histone binding to DNA. Proc Natl Acad Sci U S A 67(3):1616–1623CrossRefGoogle Scholar
  22. 22.
    Inoue A, Fujimoto D (1969) Enzymatic deacetylation of histone. Biochem Biophys Res Commun 36(1):146–150CrossRefGoogle Scholar
  23. 23.
    Lopez-Rodas G, Brosch G, Georgieva EI, Sendra R, Franco L, Loidl P (1993) Histone deacetylase. A key enzyme for the binding of regulatory proteins to chromatin. FEBS Lett 317(3):175–180CrossRefGoogle Scholar
  24. 24.
    Glaser KB (2007) HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol 74(5):659–671.  https://doi.org/10.1016/j.bcp.2007.04.007 CrossRefPubMedGoogle Scholar
  25. 25.
    Harrison IF, Dexter DT (2013) Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease? Pharmacol Ther 140(1):34–52.  https://doi.org/10.1016/j.pharmthera.2013.05.010 CrossRefPubMedGoogle Scholar
  26. 26.
    Ni X, Li L, Pan G (2015) HDAC inhibitor-induced drug resistance involving ATP-binding cassette transporters (review). Oncol Lett 9(2):515–521.  https://doi.org/10.3892/ol.2014.2714 CrossRefPubMedGoogle Scholar
  27. 27.
    Dokmanovic M, Clarke C, Marks PA (2007) Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 5(10):981–989.  https://doi.org/10.1158/1541-7786.MCR-07-0324 CrossRefPubMedGoogle Scholar
  28. 28.
    Kavanaugh SM, White LA, Kolesar JM (2010) Vorinostat: a novel therapy for the treatment of cutaneous T-cell lymphoma. Am J Health Syst Pharm 67(10):793–797.  https://doi.org/10.2146/ajhp090247 CrossRefPubMedGoogle Scholar
  29. 29.
    Liu J, Li Y (2015) Trichostatin A and tamoxifen inhibit breast cancer cell growth by miR-204 and ERalpha reducing AKT/mTOR pathway. Biochem Biophys Res Commun 467(2):242–247.  https://doi.org/10.1016/j.bbrc.2015.09.182 CrossRefPubMedGoogle Scholar
  30. 30.
    Terranova-Barberio M, Roca MS, Zotti AI, Leone A, Bruzzese F, Vitagliano C, Scogliamiglio G, Russo D et al (2016) Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression. Oncotarget 7(7):7715–7731.  https://doi.org/10.18632/oncotarget.6802 CrossRefPubMedGoogle Scholar
  31. 31.
    Tiffon C, Adams J, van der Fits L, Wen S, Townsend P, Ganesan A, Hodges E, Vermeer M et al (2011) The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells. Br J Pharmacol 162(7):1590–1602.  https://doi.org/10.1111/j.1476-5381.2010.01188.x CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Duan H, Wang C, Zhou K, Wang T, Li Y, Qiu D, Li Q, Zhang Y et al (2017) The effect of histone deacetylase inhibition on the expression of P-glycoprotein in human placental trophoblast cell lines. Placenta 49:37–47.  https://doi.org/10.1016/j.placenta.2016.11.011 CrossRefPubMedGoogle Scholar
  33. 33.
    El-Khoury V, Breuzard G, Fourre N, Dufer J (2007) The histone deacetylase inhibitor trichostatin a downregulates human MDR1 (ABCB1) gene expression by a transcription-dependent mechanism in a drug-resistant small cell lung carcinoma cell line model. Br J Cancer 97(4):562–573.  https://doi.org/10.1038/sj.bjc.6603914 CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Xu Y, Jiang Z, Yin P, Li Q, Liu J (2012) Role for class I histone deacetylases in multidrug resistance. Exp Cell Res 318(3):177–186.  https://doi.org/10.1016/j.yexcr.2011.11.010 CrossRefPubMedGoogle Scholar
  35. 35.
    Duan H, Zhou K, Zhang Y, Yue P, Wang T, Li Y, Qiu D, Wu J et al (2017) HDAC2 was involved in placental P-glycoprotein regulation both in vitro and vivo. Placenta 58:105–114.  https://doi.org/10.1016/j.placenta.2017.08.077 CrossRefPubMedGoogle Scholar
  36. 36.
    Poller B, Gutmann H, Krahenbuhl S, Weksler B, Romero I, Couraud PO, Tuffin G, Drewe J et al (2008) The human brain endothelial cell line hCMEC/D3 as a human blood–brain barrier model for drug transport studies. J Neurochem 107(5):1358–1368CrossRefGoogle Scholar
  37. 37.
    Weksler B, Romero IA, Couraud PO (2013) The hCMEC/D3 cell line as a model of the human blood brain barrier. Fluids Barriers CNS 10(1):16.  https://doi.org/10.1186/2045-8118-10-16 CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Weksler BB, Subileau EA, Perriere N, Charneau P, Holloway K, Leveque M, Tricoire-Leignel H, Nicotra A et al (2005) Blood–brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J 19(13):1872–1874.  https://doi.org/10.1096/fj.04-3458fje CrossRefPubMedGoogle Scholar
  39. 39.
    Bircsak KM, Gibson CJ, Robey RW, Aleksunes LM (2013) Assessment of drug transporter function using fluorescent cell imaging. Curr Protoc Toxicol 57:Unit 23 26.  https://doi.org/10.1002/0471140856.tx2306s57 CrossRefGoogle Scholar
  40. 40.
    Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Hardwick JS, Reilly JF, Loboda A et al (2009) Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 27(12):2052–2058.  https://doi.org/10.1200/JCO.2008.19.0694 CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Frommel TO, Coon JS, Tsuruo T, Roninson IB (1993) Variable effects of sodium butyrate on the expression and function of the MDR1 (P-glycoprotein) gene in colon carcinoma cell lines. Int J Cancer 55(2):297–302CrossRefGoogle Scholar
  42. 42.
    Shin BS, Bulitta JB, Balthasar JP, Kim M, Choi Y, Yoo SD (2011) Prediction of human pharmacokinetics and tissue distribution of apicidin, a potent histone deacetylase inhibitor, by physiologically based pharmacokinetic modeling. Cancer Chemother Pharmacol 68(2):465–475.  https://doi.org/10.1007/s00280-010-1502-y CrossRefPubMedGoogle Scholar
  43. 43.
    Wang X, Sykes DB, Miller DS (2010) Constitutive androstane receptor-mediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood–brain barrier. Mol Pharmacol 78(3):376–383.  https://doi.org/10.1124/mol.110.063685 CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    To KK, Polgar O, Huff LM, Morisaki K, Bates SE (2008) Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells. Mol Cancer Res 6(1):151–164.  https://doi.org/10.1158/1541-7786.MCR-07-0175 CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, MacGregore-Cortelli B, Tong W et al (2005) Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23(17):3923–3931.  https://doi.org/10.1200/JCO.2005.14.167 CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Wang Y, Hao D, Stein WD, Yang L (2006) A kinetic study of Rhodamine123 pumping by P-glycoprotein. Biochim Biophys Acta 1758(10):1671–1676.  https://doi.org/10.1016/j.bbamem.2006.06.004 CrossRefPubMedGoogle Scholar
  47. 47.
    van Groenigen M, Valentijn LJ, Baas F (1993) Identification of a functional initiator sequence in the human MDR1 promoter. Biochim Biophys Acta 1172(1–2):138–146CrossRefGoogle Scholar
  48. 48.
    Dauchy S, Miller F, Couraud PO, Weaver RJ, Weksler B, Romero IA, Scherrmann JM, De Waziers I et al (2009) Expression and transcriptional regulation of ABC transporters and cytochromes P450 in hCMEC/D3 human cerebral microvascular endothelial cells. Biochem Pharmacol 77(5):897–909.  https://doi.org/10.1016/j.bcp.2008.11.001 CrossRefPubMedGoogle Scholar
  49. 49.
    Bauer B, Hartz AM, Fricker G, Miller DS (2004) Pregnane X receptor up-regulation of P-glycoprotein expression and transport function at the blood–brain barrier. Mol Pharmacol 66(3):413–419.  https://doi.org/10.1124/mol.66.3 CrossRefPubMedGoogle Scholar
  50. 50.
    Lemmen J, Tozakidis IE, Galla HJ (2013) Pregnane X receptor upregulates ABC-transporter Abcg2 and Abcb1 at the blood–brain barrier. Brain Res 1491:1–13.  https://doi.org/10.1016/j.brainres.2012.10.060 CrossRefPubMedGoogle Scholar
  51. 51.
    Wang X, Campos CR, Peart JC, Smith LK, Boni JL, Cannon RE, Miller DS (2014) Nrf2 upregulates ATP binding cassette transporter expression and activity at the blood–brain and blood–spinal cord barriers. J Neurosci 34(25):8585–8593.  https://doi.org/10.1523/JNEUROSCI.2935-13.2014 CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Wang X, Hawkins BT, Miller DS (2011) Aryl hydrocarbon receptor-mediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood–brain barrier. FASEB J 25(2):644–652.  https://doi.org/10.1096/fj.10-169227 CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Kim SN, Kim NH, Lee W, Seo DW, Kim YK (2009) Histone deacetylase inhibitor induction of P-glycoprotein transcription requires both histone deacetylase 1 dissociation and recruitment of CAAT/enhancer binding protein beta and pCAF to the promoter region. Mol Cancer Res 7(5):735–744.  https://doi.org/10.1158/1541-7786.MCR-08-0296 CrossRefPubMedGoogle Scholar
  54. 54.
    Tabe Y, Konopleva M, Contractor R, Munsell M, Schober WD, Jin L, Tsutsumi-Ishii Y, Nagaoka I et al (2006) Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells. Blood 107(4):1546–1554.  https://doi.org/10.1182/blood-2004-10-4126 CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Clayton AL, Hebbes TR, Thorne AW, Crane-Robinson C (1993) Histone acetylation and gene induction in human cells. FEBS Lett 336(1):23–26CrossRefGoogle Scholar
  56. 56.
    Lee DY, Hayes JJ, Pruss D, Wolffe AP (1993) A positive role for histone acetylation in transcription factor access to nucleosomal DNA. Cell 72(1):73–84CrossRefGoogle Scholar
  57. 57.
    Turner BM (1991) Histone acetylation and control of gene expression. J Cell Sci 99(Pt 1):13–20PubMedGoogle Scholar
  58. 58.
    Wolffe AP (1996) Histone deacetylase: a regulator of transcription. Science 272(5260):371–372CrossRefGoogle Scholar
  59. 59.
    Sundseth R, MacDonald G, Ting J, King AC (1997) DNA elements recognizing NF-Y and Sp1 regulate the human multidrug-resistance gene promoter. Mol Pharmacol 51(6):963–971CrossRefGoogle Scholar
  60. 60.
    Hatherell K, Couraud PO, Romero IA, Weksler B, Pilkington GJ (2011) Development of a three-dimensional, all-human in vitro model of the blood–brain barrier using mono-, co-, and tri-cultivation Transwell models. J Neurosci Methods 199(2):223–229.  https://doi.org/10.1016/j.jneumeth.2011.05.012 CrossRefPubMedGoogle Scholar
  61. 61.
    Kulczar C, Lubin KE, Lefebvre S, Miller DW, Knipp GT (2017) Development of a direct contact astrocyte-human cerebral microvessel endothelial cells blood–brain barrier coculture model. J Pharm Pharmacol 69(12):1684–1696.  https://doi.org/10.1111/jphp.12803 CrossRefPubMedGoogle Scholar
  62. 62.
    You D, Shin HM, Mosaad F, Richardson J, Aleksunes L (2019) Brain-region specific regulation of histone acetylation and efflux transporters in mice. J Biochem Mol Toxicol.  https://doi.org/10.1002/jbt.22318

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Joint Graduate Program in ToxicologyRutgers, The State University of New JerseyPiscatawayUSA
  2. 2.Department of Pharmacology and Toxicology, Ernest Mario School of PharmacyRutgers, The State University of New JerseyPiscatawayUSA
  3. 3.Environmental and Occupational Health Sciences InstitutePiscatawayUSA
  4. 4.Robert Stempel School of Public Health and Social WorkFlorida International UniversityMiamiUSA

Personalised recommendations